Patents Examined by Sarah Pihonak
  • Treating of side-effects resulting from chemodenervation
    Patent number: 11129822
    Abstract: The present disclosure relates generally to methods of restoring neuromuscular transmission by locally administering an effective dose of a composition comprising an anticholinesterase to a non-responsive muscle. The disclosure also relates to methods of reversing a neurotoxin-induced muscle paralysis or muscle weakness, the method comprising locally administering a composition comprising an anticholinesterase to the patient.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: September 28, 2021
    Inventor: Mary Gardner
  • Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
    Patent number: 11129397
    Abstract: The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 28, 2021
    Assignee: FIREMENICH INCORPORATED
    Inventors: Catherine Tachdjian, Donald Karanewsky, Xiao Qing Tang, Hanghui Liu
  • Methods of treating schizophrenia
    Patent number: 11129807
    Abstract: Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, provided herein are methods of determining the prominent symptom domain of a subject suffering from schizophrenia. Further, provided herein are various methods for the treatment of the negative symptoms, cognitive dysfunction symptoms, or both, associated with schizophrenia comprising administering to a subject a therapeutically or prophylactically effective amount of various compounds.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: September 28, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Seth Hopkins, Kenneth Koblan, Antony Loebel, Ajay Ogirala
  • Igmesine for use in the treatment of neurodegenerative diseases
    Patent number: 11129801
    Abstract: The present invention relates to methods for treating neurodegenerative diseases and disorders with igmesine.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 28, 2021
    Assignee: SigmaThera SAS
    Inventors: François J. Roman, Johann Meunier
  • Auris formulations for treating otic diseases and conditions
    Patent number: 11123286
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: September 21, 2021
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • HER3 ligands and uses thereof
    Patent number: 11124483
    Abstract: Described herein, inter alia, are compositions of HER3 ligands and methods for treating diseases using the same.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 21, 2021
    Assignee: The Regents of the University of California
    Inventors: Christopher Novotny, Kevan Shokat, Natalia Jura
  • Auris formulations for treating OTIC diseases and conditions
    Patent number: 11123285
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: September 21, 2021
    Assignees: Otonomy, Inc., The Regents of the University of California
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Meclozine derivatives and diclazuril derivatives for use in the prevention and/or the treatment of disorders associated to the inflammation induced by
    Patent number: 11116763
    Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: September 14, 2021
    Assignees: Universite de Paris, Assistance Publique—Hopitaux de Paris
    Inventors: Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
  • Apremilast pharmaceutical compositions
    Patent number: 11110077
    Abstract: The present invention relates to topical pharmaceutical compositions of apremilast used for the treatment of psoriasis and/or psoriatic arthritis. It further relates to processes of preparation of the compositions and the method of use for these compositions.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 7, 2021
    Assignee: SARUDBHAVA FORMULATIONS PRIVATE LIMITED
    Inventor: Venkata Nookaraju Sreedharala
  • Methods for treating liver disorders using FXR agonists
    Patent number: 11110083
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 7, 2021
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
  • Chewable dosage forms containing sitagliptin and metformin
    Patent number: 11096890
    Abstract: The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof; a fully or partially pregelatinized starch, a polyethylene glycol polymer; a lubricant; an emulsifier; a flavoring agent; and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 24, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wycliffe S. Omwancha, Rubi Burlage
  • Use of nicotinic acetylcholine receptor alpha 7 activators
    Patent number: 11096916
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: August 24, 2021
    Assignee: Novartis AG
    Inventors: Therese Di Paolo, Dominik Feuerbach, Baltazar Gomez-Mancilla, Donald Johns
  • Pharmaceutical composition
    Patent number: 11096928
    Abstract: The present invention relates to a pharmaceutical composition comprising: (a) at least one neutral endopeptidase inhibitor or a pharmaceutically acceptable salt or ester thereof, (b) at least one compound represented by formula (I) or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier. Combined administration showed better medicinal effects than separate administration.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 24, 2021
    Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Chaodong Wang, Yongkai Chen, Liu Hu, Xian Zeng, Daiwu Kang
  • Pridopidine for treating huntington's disease
    Patent number: 11090297
    Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: August 17, 2021
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Merav Bassan, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
  • Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
    Patent number: 11090275
    Abstract: The invention provides synergistic combinations of cannabidiol (CBD) and a second therapeutic agent, such as one or more ChEH/AEBS inhibitors, a naphthoquinone or a derivative thereof, or any combination thereof, effective for the treatment cancer. Compositions containing same and methods of use of same are described.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 17, 2021
    Assignee: JAY PHARMA INC.
    Inventors: Ilana Nathan, Zvi Vogel, Lakshmi Narasaiah Uppalapati, Adela Juknat Geralnik
  • Method for treating movement disorders with befiradol
    Patent number: 11090298
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: August 17, 2021
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
  • Butyrate salts for use in inflammatory diseases
    Patent number: 11083700
    Abstract: This invention relates to preparations comprising a butyrate salt for enteral administration for use in the treatment of conditions and diseases that are not diseases or conditions of the intestine and/or are associated with systemic inflammation. Preparations comprising a butyrate salt for enteral administration were found useful in the treatment of osteoarthritis, Parkinson's disease, migraine, idiopathic subfertility, hangovers, and gout.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: August 10, 2021
    Assignee: BIRRBEHEER B.V.
    Inventor: Jan Pieter Willem Vermeiden
  • Lactams for use in the treatment of skin lesions
    Patent number: 11083706
    Abstract: Lactams for use in the treatment of skin lesions are described. In particular, lactams for the treatment of chronic wounds, including chronic wounds in patients having diabetes.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: August 10, 2021
    Assignee: Conopco, Inc.
    Inventors: Neil James Parry, Paolo Pantalone, Paul Williams
  • Epinephrine compositions and containers
    Patent number: 11083698
    Abstract: The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: August 10, 2021
    Assignee: NEVAKAR INC.
    Inventors: Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
  • Compositions and methods useful for treatment of respiratory illness
    Patent number: 11083697
    Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: August 10, 2021
    Assignee: The Procter & Gamble Company
    Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines